Technology test bed engine real-time failure control

The Real-Time Failure Control (RTFC) program involves development of a failure detection algorithm, for the Space Shuttle Main Engine (SSME). This failure detection approach is signal-based and entails monitoring SSME measurement signals based on predetermined as well as on-line computed mean and standard deviation values. Twenty-four engine measurements are monitored in the algorithm and provisions are made to add more parameters if needed. Each of the first values of every measurement signal at the algorithm start is checked against safety limits placed around a pre-computed engine-to-engine mean value (MV) with a bandwidth equal to a given multiple of the pre-computed standard deviation (SD). If several parameters are out of the bounds of these limits a failure is signaled. During the first two seconds (after algorithm start) a moving average (MA) and a SD is computed on-line in real-time. The moving average of each parameter is computed by averaging the incoming signal measurement with the four most recent previous signal measurements. The moving average is updated at every sampling interval (40 msec) and is checked against a similar safety band around the initial signal value for each parameter. If several anomalies are registered, a failure is signaled by the algorithm. At the end of the two-second interval the MA is fixed as the mean value for the rest of the algorithm operation and a safety band is placed above and below this value equal to a multiple of the computed SD. However, the safety band is adjusted by adjusting the mean value when propellant tank repressurization and venting take place. 'Influence Coefficients' are used to make the necessary adjustments to the safety limits of those parameters that are affected by repressurization and venting or valve closure and opening. The MA is, in both cases, continuously updated and checked against the safety band. Once more, if several parameters exceed the limits a failure is signaled. At the start of every scheduled power transient the algorithm is stopped. It is re-initiated after two seconds from the termination of the power transient and the process is repeated. The final report is divided into four major sections. The most encompassing of all is the discussion section that has sub-sections on: (1) RTFC algorithm development, (2) RTFC simulations; (3) RTFC current limitations; and (4) enhancements planned for

Real-time failure control (SAFD)

The Real Time Failure Control program involves development of a failure detection algorithm, referred as System for Failure and Anomaly Detection (SAFD), for the Space Shuttle Main Engine (SSME). This failure detection approach is signal-based and it entails monitoring SSME measurement signals based on predetermined and computed mean values and standard deviations. Twenty four engine measurements are included in the algorithm and provisions are made to add more parameters if needed. Six major sections of research are presented: (1) SAFD algorithm development; (2) SAFD simulations; (3) Digital Transient Model failure simulation; (4) closed-loop simulation; (5) SAFD current limitations; and (6) enhancements planned for

Modeling Techniques for Evaluation the Effectiveness of Particle Damping in Turbomachinery

High power turbopumps are frequently used to supply propellants to the combustion chambers of rocket engines. Due to the high pressures and flow-rates required, turbopump components are subjected to harsh environments which include dynamic excitation due to random, sine, and acoustic vibration. Additionally, fluid-induced forces can couple with the dynamics of the structure resulting in flow induced instabilities (flutter). Structural response to these forms of excitation results in reduced fatigue life and increases the likelihood of an operational failure. Particle damping has been used successfully on vibration problems in the past by increasing the damping and therefore reducing the response to acceptable levels. Empirical methods have typically been employed to evaluate the performance of the particles in reducing the structural response. This report explores the use of finite element methods to estimate the effectiveness of particle damping in a typical non-rotating turbopump component. Axisymmetric harmonic models are used to estimate the increase in modal damping produced by the addition of particles in the cavity of an axisymmetric seal. Target modes of vibration are evaluated to quantify how the effective particle damping is altered by geometry changes in the seal design. A new method to predict the performance of particle dampers is developed and shown to provide more reasonable estimates of damping

Contrôle de la chiralité axiale à l’aide d’arynes et en absence de métaux de transition

International audienceThe modular construction of enantioenriched biaryl derivatives is presented. This approach is based on (a) an almost quantitative access to polybrominated precursors via a transition metal-free aryl-aryl coupling, the ARYNE-coupling, (b) the regioselective introduction of a traceless chiral auxiliary (an enantiopure para-tolylsulfinyl group), (c) the chemoselective functionalization of this auxiliary and (d) subsequent regioselective functionalization of the remaining bromine atoms without any racemization during these steps. Next, the atropo-selective coupling of in situ generated arynes and aryllithiums bearing various chiral auxiliaries (tert-butylsulfoxide, para-tolylsulfoxide, tartrate-derived chiral diethers and oxazolines) is described and applied to the formal synthesis of (-)-steganacin. La construction modulaire de dérivés biaryliques énantioenrichis est présentée. Cette approche est basée sur (a) un accès quasi quantitatif aux précurseurs polybromés via un 2 couplage aryle-aryle sans métaux de transition, le couplage ARYNE, (b) l'introduction régiosélective d'un auxiliaire chiral (un groupe para-tolylsulfinyl énantiopur), (c) la fonctionnalisation chimiosélective de cet auxiliaire et (d) la fonctionnalisation régiosélective subséquente des atomes de brome restants sans racémisation au cours de ces étapes. Ensuite, le couplage atropo-sélectif à l'aide d'arynes générés in situ et d'aryllithiums portant divers auxiliaires chiraux (tert-butylsulfoxyde, para-tolylsulfoxide, diéthers dérivés du tartrate et des oxazolines chirales) est décrit et appliqué à la synthèse formelle de la (-)-stéganacine

Transition-Metal-Free Synthesis of a Known Intermediate in the Formal Synthesis of (-)-Steganacin

International audienceThe formal synthesis of both enantiomers of a natural axially chiral biaryl, steganacin is reported. The previously developed atropo-diastereoselective coupling of an aryne and an aryllithium (the 'ARYNE coupling') allows for this synthesis. In each step, the axial configuration of the biaryl could be maintained. The key intermediate of literature was accessed without using transition metals, demonstrating the interest of the ARYNE coupling as a complement or an alternative to transition metal-catalyzed couplings

The relationship of primary health care use with persistence of insomnia: a prospective cohort study

<p>Abstract</p> <p>Background</p> <p>Prevalence of insomnia symptoms in the general population is high. Insomnia is linked with high health care use and within primary care there are a number of treatment options available. The objective of this study was to determine the association of persistence and remission of insomnia with primary health care using a longitudinal study.</p> <p>Methods</p> <p>A postal survey of registered adult (over 18 years) populations of five UK general practices, repeated after 1 year, linked to primary care records. Baseline survey responders were assessed for persistence of insomnia symptoms at 12 months. The association of primary care consultation or prescription for any mood disorder (defined as anxiety, depression, stress, neurosis, or insomnia) in the 12 months between baseline and follow-up surveys with persistence of insomnia was determined.</p> <p>Results</p> <p>474 participants reporting insomnia symptoms at baseline were followed up at 12 months. 131(28%) consulted for mood problem(s) or received a relevant prescription. Of these 100 (76%) still had insomnia symptoms at one year, compared with 227 (66%) of those with no contact with primary care for this condition (OR 1.37; 95% CI 0.83, 2.27). Prescription of hypnotics showed some evidence of association with persistence of insomnia at follow-up (OR 3.18; 95% CI 0.93, 10.92).</p> <p>Conclusion</p> <p>Insomniacs continue to have problems regardless of whether or not they have consulted their primary care clinician or received a prescription for medication over the year. Hypnotics may be associated with persistence of insomnia. Further research is needed to determine more effective methods of identifying and managing insomnia in primary care. There may however be a group who have unmet need such as depression who would benefit from seeking primary health care.</p

Safety profile of Coartem®: the evidence base

This article reviews the comprehensive data on the safety and tolerability from over 6,300 patients who have taken artemether/lumefantrine (Coartem®) as part of Novartis-sponsored or independently-sponsored clinical trials. The majority of the reported adverse events seen in these studies are mild or moderate in severity and tend to affect the gastrointestinal or nervous systems. These adverse events, which are common in both adults and children, are also typical of symptoms of malaria or concomitant infections present in these patients. The wealth of safety data on artemether/lumefantrine has not identified any neurological, cardiac or haematological safety concerns. In addition, repeated administration is not associated with an increased risk of adverse drug reactions including neurological adverse events. This finding is especially relevant for children from regions with high malaria transmission rates who often receive many courses of anti-malarial medications during their lifetime. Data are also available to show that there were no clinically relevant differences in pregnancy outcomes in women exposed to artemether/lumefantrine compared with sulphadoxine-pyrimethamine during pregnancy. The six-dose regimen of artemether/lumefantrine is therefore well tolerated in a wide range of patient populations. In addition, post-marketing experience, based on the delivery of 250 million treatments as of July 2009, has not identified any new safety concerns for artemether/lumefantrine apart from hypersensitivity and allergies, known class effects of artemisinin derivatives